A look at the international race to create human eggs and sperm in the lab
By Rob Stein, Regina G. Barber, Berly McCoy,
NPR [cites CGS' Marcy Darnovsky]
| 11. 29. 2023
In which we meet the pioneers of one of the most exciting — and controversial — fields of biomedical research: in vitro gametogenesis, or IVG.
The goal of IVG is to make unlimited supplies of what Hayashi calls "artificial" eggs and sperm from any cell in the human body. That could let anyone — older, infertile, single, gay, trans — have their own genetically related babies. As such, the field opens up a slew of ethical concerns.
But that isn't stopping researchers from pressing forward.
So, this episode NPR science correspondent Rob Stein gives us a glimpse into the global race to create the first artificial human embryos to see how the competition is unfolding.
Related Articles
By Sarojini Nadimpally and Gargi Mishra, The Wire | 12.15.2024
In-vitro fertilisation (IVF) as assisted reproductive technology (ART) has been in vogue for quite a few decades now. While IVF has been hailed as a significant scientific advancement, with many advantages, here are some limitations which bear keeping in mind...
Image by Mohamed Hassan from Pixabay
It is hard to make predictions, especially about the future, as Yogi Berra, Niels Bohr, and other luminaries have remarked. But there are already signs that the incoming Trump administration may have some difficulty establishing consistent policies about controversial issues concerning human reproduction.
On the one hand, consider “the conservative blueprint for a second Trump administration.”
The notorious Project 2025’s Mandate for Leadership seeks to delete terms such as “reproductive rights” from “every federal...
By Susan Dominus, The New York Times | 11.30.2024
In the days after Daphna Cardinale delivered her second child, she experienced a rare sense of calm and wonder. The feeling was a relief after so much worrying: She and her husband, Alexander, had tried for three years to conceive...
By Christy Santhosh, Reuters | 11.27.2024
Nov 27 (Reuters) - The U.S. Food and Drug Administration is weighing the need for regulatory action on bluebird bio's (BLUE.O), opens new tab gene therapy for a rare neurological disorder, it said on Wednesday, as the agency probes additional...
